Merck & Co. is driving forward in its quest to develop a premier immuno-oncology pipeline with the acquisition of Australia-based Viralytics Ltd. and its oncolytic immunotherapy treatments.
Nevada-based PDL BioPharma will no longer pursue a proposed acquisition of Neos Therapeutics. PDL made three failed attempts to acquire Texas-based Neos.
Roche Holding will buy the rest of U.S. cancer data company Flatiron Health that the Swiss drugmaker does not already own for $1.9 billion to speed development of cancer medicines.
Shares of Teva Pharmaceutical were up following news reports that billionaire investor Warren Buffett took a stake in the company.
Charles River Laboratories, a contract research organization (CRO) with headquarters in Wilmington, Mass., is buying MPI Research for about $800 million.
Allergan Plc reported better-than-expected fourth-quarter 2017 profit and announced positive data on one of the two migraine treatments it is developing.
Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
A federal judge sentenced Aegerion for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the victims.
Rare disease giant Shire plc purchased a preclinical autoimmune drug candidate being developed by AB Biosciences.